Taro Pharmaceuticals USA, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$35.7M
Doctors Paid
2,699
Transactions
17,779
2023 Total
$3.2M
Payment Breakdown by Category
Research$35.3M (98.9%)
Food & Beverage$128,928 (0.4%)
Consulting$104,871 (0.3%)
Travel$22,618 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $35.3M | 3,536 | 98.9% |
| Food and Beverage | $128,928 | 7,673 | 0.4% |
| Honoraria | $117,100 | 36 | 0.3% |
| Consulting Fee | $104,871 | 81 | 0.3% |
| Education | $34,401 | 6,394 | 0.1% |
| Travel and Lodging | $22,618 | 59 | 0.1% |
Payments by Type
Research
$35.3M
3,536 transactions
General
$407,918
14,243 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study in the Treatment of Inflammatory Lesions of Rosacea | $3.5M | 0 | 285 |
| Study | $2.8M | 0 | 283 |
| BTCG 1808 | $2.2M | 0 | 154 |
| A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo | $2.2M | 0 | 564 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy And Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis | $2.1M | 0 | 323 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis | $2.1M | 0 | 329 |
| Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris | $1.4M | 0 | 92 |
| IVRC 2002 | $1.3M | 0 | 148 |
| TaroLCNZ 1618 | $1.2M | 12 | 124 |
| A Multi-center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Tretinoin Cream 0.025% (Taro Pharmaceuticals U.S.A) and RETIN-A (Tretinoin) Cream 0.025% and Both Active Treatment to a Placebo Control in the Treatment of Acne Vulgaris | $1.2M | 0 | 51 |
| TaroAZAG 1533 | $1.1M | 34 | 135 |
| Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2 and Naftin Gel 2 in Tinea Pedis | $1.0M | 0 | 65 |
| A Multi-center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.1% (XXXXXX) to Differin Gel (Adapalene 0.1%, Galderma) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris | $975,059 | 0 | 51 |
| TaroIVRL 1604 | $953,480 | 4 | 24 |
| RXLC 2118 | $772,659 | 0 | 97 |
| TRTN 1619 | $723,494 | 0 | 29 |
| To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15 Topical Gel | $717,139 | 0 | 78 |
| An Open-Label Study to Assess Safety | $681,290 | 0 | 44 |
| A Randomized, Double-Blind, Multiple Center Placebo Controlled Study Comparing Taro Product to RLD and Both Treatments to a Placebo Control in the Treatment of Acne Vulgaris | $674,699 | 0 | 35 |
| Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study | $670,453 | 0 | 83 |
| A Randomized, Double-Blind, Parallel, Multi-Center, Placebo-Controlled Study in the Treatment of Tinea Pedis | $607,910 | 0 | 36 |
| TaroDCSG 1621 | $591,704 | 8 | 82 |
| TaroTRTC 1623 | $427,142 | 3 | 18 |
| CTBC 1705 | $418,068 | 0 | 41 |
| TaroTRTC 1622 | $413,362 | 4 | 18 |
| A Study Comparing Tretinoin Gel Microsphere, 0.1 and RETIN-A MICRO Gel Microsphere, 0.1 in the Treatment of Acne Vulgaris | $368,218 | 0 | 20 |
| TaroNFTC 1722 | $341,616 | 11 | 19 |
| TaroADPS 1602 | $304,399 | 5 | 11 |
| DXPN 1807 | $269,990 | 0 | 15 |
| TaroDPSG 1517 | $238,347 | 6 | 14 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2017 |
|---|---|---|---|---|
| Dr. Reinhard Rott, Md-Mba, MD-MBA | Specialist | Temple Terrace, FL | $1.4M | $0 |
| Dr. Hector Wiltz Jr, M.d, M.D | Dermatology | Miami, FL | $726,049 | $0 |
| Dr. Francisco Flores, M.d, M.D | MOHS-Micrographic Surgery | Miramar, FL | $661,304 | $0 |
| Mr. Reginald Williams, Md, MD | Surgery | Jesup, GA | $440,177 | $0 |
| Dr. Joe Blumenau, M.d., F.a.a.f.p, M.D., F.A.A.F.P | Family Medicine | Dallas, TX | $421,750 | $0 |
| Dr. Jeanette Straga | Neurological Surgery | Pahrump, NV | $396,181 | $0 |
| Unknown Provider | — | — | $346,147 | $0 |
| Lydie Hazan, Md, MD | Nutrition, Pediatric | Beverly Hills, CA | $299,274 | $0 |
| Salma Saiger, M.d, M.D | Internal Medicine | Mesquite, TX | $146,636 | $0 |
| Omar Benitez, Md, MD | General Practice | Miami, FL | $122,432 | $0 |
| Dr. James Moretti, M.d, M.D | Family Medicine | Pittsburgh, PA | $106,585 | $0 |
| Dr. Sergio Ibarra, Md, MD | Emergency Medicine | El Paso, TX | $85,364 | $0 |
| Dr. Yamirka Duardo-Guerra, M.d, M.D | Family Medicine | Miami, FL | $84,621 | $0 |
| Dr. Zoe Draelos, M.d, M.D | Dermatology | High Point, NC | $83,879 | $0 |
| Dr. Stephen Schleicher, M.d, M.D | MOHS-Micrographic Surgery | Sugarloaf, PA | $80,944 | $0 |
| Dr. Frances Herbert, M.d, M.D | Specialist | Plano, TX | $80,559 | $0 |
| Shahram Jacobs, M.d, M.D | Internal Medicine | Encino, CA | $79,047 | $0 |
| Mr. Jaime Garcia, M.d, M.D | Dermatology | Hialeah, FL | $76,800 | $0 |
| Leon Kircik, Md, MD | Dermatology | Lousiville, KY | $65,102 | $0 |
| Dr. Hernando Alvarez, Md, MD | Adult Medicine | Hialeah, FL | $58,400 | $0 |
| Tooraj Raoof, Md, MD | Internal Medicine | Encino, CA | $47,328 | $0 |
| Gregory Samano, Do, DO | Family Medicine | Altamonte Springs, FL | $36,669 | $0 |
| Unknown Provider | — | — | $25,100 | $0 |
| Joseph Scott, Md, MD | General Practice | Denton, TX | $21,990 | $0 |
| Dr. Harold Farber, M.d,, M.D, | Dermatology | Philadelphia, PA | $17,029 | $0 |
Ad
Top Products
- Topicort Spray 0.25% $6.1M
- TRETINOIN $402,041
Associated Products (8)
- Topicort Spray 0.25% $6.1M
- TRETINOIN $402,041
- TOPICORT (desoximetasone) Topical Spray, 0.25% $260,469
- ADAPALENE $96,605
- Topicort $43,560
- ULTRAVATE (halobetasol propionate) lotion $20,262
- HALOG OINTMENT (Halcinonide Ointment, USP) 0.1% $19,803
- HALOG (Halcinonide Cream, USP) 0.1% $15,374
Payment Categories
- Food & Beverage $128,928
- Consulting $104,871
- Travel & Lodging $22,618
- Research $35.3M
About Taro Pharmaceuticals USA, Inc.
Taro Pharmaceuticals USA, Inc. has made $35.7M in payments to 2,699 healthcare providers, recorded across 17,779 transactions in the CMS Open Payments database. In 2023, the company paid $3.2M. The top product by payment volume is Topicort Spray 0.25% ($6.1M).
Payments were distributed across 54 medical specialties. The top specialty by payment amount is Specialist ($1.5M to 179 doctors).
Payment categories include: Food & Beverage ($128,928), Consulting ($104,871), Research ($35.3M), Travel & Lodging ($22,618).
Taro Pharmaceuticals USA, Inc. is associated with 8 products in the CMS Open Payments database, including Topicort Spray 0.25%, TRETINOIN, and TOPICORT (desoximetasone) Topical Spray, 0.25%.